Condition: Hepatocellular Carcinoma Non-resectable · Sponsor: Fujian Provincial Hospital
This is an Open-label, Multicenter, Phase II clinical trial to evaluate the efficacy and safety of Transcatheter arterial chemoembolization (TACE), Lenvatinib combination with Sintilimab (Triple Therapy) sequential radiotherapy in patients with Unresectable Hepatocellular Carcinoma (uHCC).
This description comes directly from the study's public registry record.
Shao-Ming Wei · (+86)13599037493 · 67468424@qq.com
Always discuss trial participation with your own doctor first.
| First Affiliated Hospital of Fujian Medical University | Fuzhou, Fujian, China | Not Yet Recruiting |
| Fujian Provincial Hospital | Fuzhou, Fujian, China | Recruiting |
| Fujian provincial hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| Mengchao Hepatobiliary Hospital of Fujian Medical University | Fuzhou, Fujian, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06561399